Buprenorphine (BioDeep_00000001442)

 

Secondary id: BioDeep_00000398419

human metabolite blood metabolite


代谢物信息卡片


(1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11-trien-11-ol

化学式: C29H41NO4 (467.30354260000007)
中文名称:
谱图信息: 最多检出来源 Mus musculus(blood) 57.41%

分子结构信息

SMILES: CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
InChI: InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1

描述信息

A derivative of the opioid alkaloid thebaine that is a more potent and longer lasting analgesic than morphine. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. [PubChem]
N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AE - Oripavine derivatives
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
D002491 - Central Nervous System Agents > D000700 - Analgesics

同义名列表

38 个代谢物同义名

(1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11-trien-11-ol; 2-[3-Cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 17-Cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-Cyclopropylmethyl-4,5a-epoxy-7a-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol; 2-(N-Cyclopropylmethyl-4,5a-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6a-yl)-3,3-dimethyl-2-butanol; 21-Cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-Cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-Cyclopropyl-7a-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; Reckitt and colman brand 2 OF buprenorphine hydrochloride; Reckitt and colman brand 1 OF buprenorphine hydrochloride; Reckitt benckiser brand OF buprenorphine hydrochloride; Schering-plough brand OF buprenorphine hydrochloride; Schering plough brand OF buprenorphine hydrochloride; Grünenthal brand OF buprenorphine hydrochloride; Reckitt brand OF buprenorphine hydrochloride; Essex brand OF buprenorphine hydrochloride; Key brand OF buprenorphine hydrochloride; Grünenthal brand OF buprenorphine; Buprenorphine grünenthal brand; Hydrochloride, buprenorphine; Buprenorphine hydrochloride; (-)-Buprenorphine; Buprenorphinum; buprenorphine; Buprenorfina; Buprenophine; RX 6029 m; RX-6029-m; RX 6029M; Temgesic; Temgésic; Buprenex; Subutex; Buprex; Prefin



数据库引用编号

18 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

5 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Ethan B Niebergall, Daron Weekley, Anna Mazur, Nathan A Olszewski, Kayla M DeSchepper, N Radant, Aishwarya S Vijay, W Christopher Risher. Abnormal Morphology and Synaptogenic Signaling in Astrocytes Following Prenatal Opioid Exposure. Cells. 2024 May; 13(10):. doi: 10.3390/cells13100837. [PMID: 38786059]
  • Davene Lynch, Lyndsey Chitty, Brittany Johnson, Amie L Hoefnagel. Suspected Buprenorphine-Precipitated Opioid Withdrawal following Intercourse: A Case Report. Journal of pain & palliative care pharmacotherapy. 2023 Dec; 37(4):314-316. doi: 10.1080/15360288.2023.2250344. [PMID: 37640398]
  • Hilton Klein, Barry L Levinson, Steven L Leary, Glenn Dobson. A pharmacokinetic study of extended-release buprenorphine in cynomolgus monkeys (Macaca fasicularis). Journal of medical primatology. 2023 12; 52(6):369-373. doi: 10.1111/jmp.12661. [PMID: 37432036]
  • Aleaya R Bowie, Katherine N Gibson-Corley, Erin Nz Yu. Pharmacokinetics of Extended-release Buprenorphine in Mongolian Gerbils (Meriones unguiculatus). Journal of the American Association for Laboratory Animal Science : JAALAS. 2023 11; 62(6):538-544. doi: 10.30802/aalas-jaalas-23-000048. [PMID: 37813575]
  • Soraya Babaie, Mohammad Charkhpour, Maryam Kouhsoltani, Hamed Hamishehkar, Ana Cláudia Paiva-Santos. Nano-invasomes for simultaneous topical delivery of buprenorphine and bupivacaine for dermal analgesia. Experimental dermatology. 2023 Jun; ?(?):. doi: 10.1111/exd.14850. [PMID: 37283479]
  • Krista R Noam, Timothy J Schmutte, Sandrine Pirard, Carol Bourdon, Daniel Langless, Robert Plant. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use. Journal of addiction medicine. 2023 May; 17(3):e199-e201. doi: 10.1097/adm.0000000000001092. [PMID: 37267183]
  • Elham Khodaverdi, Farzin Hadizadeh, Nilofarsadat Hoseini, Farhad Eisvand, Mohadeseh Tayebi, Hossein Kamali, Fatemeh Oroojalian. In-vitro and in-vivo evaluation of sustained-release buprenorphine using in-situ forming lipid-liquid crystal gels. Life sciences. 2023 Feb; 314(?):121324. doi: 10.1016/j.lfs.2022.121324. [PMID: 36574944]
  • Guan-Yu Zhuo, Ming-Chi Chen, Tzu-Yu Lin, Shih-Ting Lin, Daniel Tzu-Li Chen, Cynthia Wei-Sheng Lee. Opioid-Modulated Receptor Localization and Erk1/2 Phosphorylation in Cells Coexpressing μ-Opioid and Nociceptin Receptors. International journal of molecular sciences. 2023 Jan; 24(2):. doi: 10.3390/ijms24021048. [PMID: 36674576]
  • Gholamreza Kheirabadi, Masoud Asadi, Mohammad Niroumand Sarvandani, Alireza Jamshidi, Faezeh Mahdavi. Risk and Protective Factors Affecting Drug Craving among Patients with Substance Use Disorders Undergoing Opioid Agonists Maintenance Therapy. Substance use & misuse. 2023; 58(13):1742-1750. doi: 10.1080/10826084.2023.2247068. [PMID: 37602742]
  • Josiah Perez. Kratom and opioid use disorder in the perioperative period: A case report on the expanding role of buprenorphine. Journal of opioid management. 2023 Jan; 19(1):91-93. doi: 10.5055/jom.2023.0762. [PMID: 36683304]
  • Yi Zhou, Xihua Lu, Yunfei Zhang, Changsheng Li, Yu Bai, Zhen Zhang. Investigation of the effects of opioids on microglial nitrite and nitric oxide synthase (iNOS) production and phagocytosis during inflammation. Combinatorial chemistry & high throughput screening. 2022 Nov; ?(?):. doi: 10.2174/1386207326666221111093915. [PMID: 36372918]
  • Marta Tikhomirov, Paweł Jajor, Tomasz Śniegocki, Błażej Poźniak. Predicting the efficacy of opioid sequestration by intravenous lipid emulsion using biologically relevant in vitro models of drug distribution. Scientific reports. 2022 11; 12(1):18683. doi: 10.1038/s41598-022-21790-4. [PMID: 36333363]
  • Kristin M Mattocks, David T Moore, Dora Lendvai Wischik, Christina M Lazar, Marc I Rosen. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic. Journal of substance abuse treatment. 2022 Aug; 139(?):108777. doi: 10.1016/j.jsat.2022.108777. [PMID: 35346533]
  • Anna Beth Parlier-Ahmad, Mickeal Pugh, Caitlin E Martin. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder. Journal of racial and ethnic health disparities. 2022 Aug; 9(4):1557-1567. doi: 10.1007/s40615-021-01095-4. [PMID: 34254271]
  • Barrot H Lambdin, Ricky N Bluthenthal, Hansel E Tookes, Lynn Wenger, Terry Morris, Paul LaKosky, Alex H Kral. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States. Drug and alcohol dependence. 2022 Aug; 237(?):109504. doi: 10.1016/j.drugalcdep.2022.109504. [PMID: 35688052]
  • Judith I Tsui, Aimee N C Campbell, Martina Pavlicova, Tse-Hwei Choo, Joshua D Lee, Ryan R Cook, Matisyahu Shulman, Edward V Nunes, John Rotrosen. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. Drug and alcohol dependence. 2022 Jul; 236(?):109469. doi: 10.1016/j.drugalcdep.2022.109469. [PMID: 35605529]
  • Nicholas Lintzeris, Rachel M Deacon, Victoria Hayes, Tracy Cowan, Llewellyn Mills, Laila Parvaresh, Lucy Harvey Dodds, Louisa Jansen, Raelene Dojcinovic, Man Cho Leung, Apo Demirkol, Therese Finch, Kristie Mammen. Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. Drug and alcohol review. 2022 Jul; 41(5):1009-1019. doi: 10.1111/dar.13382. [PMID: 34520592]
  • Hiroko Enomoto, Lydia Love, Melanie Madsen, Amber Wallace, Kristen M Messenger. Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs. Journal of veterinary pharmacology and therapeutics. 2022 Jul; 45(4):358-365. doi: 10.1111/jvp.13056. [PMID: 35445748]
  • Kevin J Freise, Craig Reinemeyer, Katherine Warren, Ting-Li Lin, Terrence P Clark. Single-dose pharmacokinetics and bioavailability of a novel extended duration transdermal buprenorphine solution in cats. Journal of veterinary pharmacology and therapeutics. 2022 Jul; 45 Suppl 1(?):S31-S39. doi: 10.1111/jvp.13044. [PMID: 35790014]
  • Lauren Textor, Daniel Ventricelli, Shoshana V Aronowitz. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States. The International journal on drug policy. 2022 Jul; 105(?):103703. doi: 10.1016/j.drugpo.2022.103703. [PMID: 35561484]
  • Ria Garg, Sophie A Kitchen, Siyu Men, Tonya J Campbell, Nikki Bozinoff, Mina Tadrous, Tony Antoniou, Jennifer Wyman, Dan Werb, Charlotte Munro, Tara Gomes. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis. Drug and alcohol dependence. 2022 Jul; 236(?):109459. doi: 10.1016/j.drugalcdep.2022.109459. [PMID: 35489179]
  • Terrence P Clark, Deborah D Linton, Kevin J Freise, Craig Reinemeyer, Kim M Newkirk, Adam Aulbach, Ting-Li Lin. Margin of safety of extended-duration transdermal buprenorphine solution following multiple-dose administrations to cats. Journal of veterinary pharmacology and therapeutics. 2022 Jul; 45 Suppl 1(?):S67-S84. doi: 10.1111/jvp.13051. [PMID: 35790012]
  • David Dadiomov, Maria Bolshakova, Melania Mikhaeilyan, Rebecca Trotzky-Sirr. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic. Harm reduction journal. 2022 Jun; 19(1):69. doi: 10.1186/s12954-022-00651-3. [PMID: 35768817]
  • Noa Krawczyk, Sachini Bandara, Sydney Merritt, Hridika Shah, Alexandra Duncan, Brendan McEntee, Maria Schiff, N Jia Ahmad, Sara Whaley, Amanda Latimore, Brendan Saloner. Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative. Addiction science & clinical practice. 2022 Jun; 17(1):30. doi: 10.1186/s13722-022-00313-6. [PMID: 35655293]
  • Aileen G Guillen, Minal Reddy, Soheil Saadat, Bharath Chakravarthy. Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review. Telemedicine journal and e-health : the official journal of the American Telemedicine Association. 2022 06; 28(6):761-767. doi: 10.1089/tmj.2021.0308. [PMID: 34714172]
  • Elizabeth D Nesoff, Megan E Marziali, Silvia S Martins. The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic. Addiction (Abingdon, England). 2022 Jun; 117(6):1781-1786. doi: 10.1111/add.15778. [PMID: 34873783]
  • Thuy Nguyen, Engy Ziedan, Kosali Simon, Jennifer Miles, Stephen Crystal, Hillary Samples, Sumedha Gupta. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. JAMA network open. 2022 06; 5(6):e2214765. doi: 10.1001/jamanetworkopen.2022.14765. [PMID: 35648400]
  • Sara N Edmond, Sophia Currie, Amanda Gehrke, Caroline G Falker, Minhee Sung, Audrey Abelleira, Ellen L Edens, William C Becker. Optimizing Interdisciplinary Virtual Pain Care and Buprenorphine Initiation During COVID-19: A Quality Improvement Study. Pain medicine (Malden, Mass.). 2022 05; 23(6):1043-1046. doi: 10.1093/pm/pnab348. [PMID: 34940877]
  • Erik Olofsen, Marijke Hyke Algera, Laurence Moss, Robert L Dobbins, Geert J Groeneveld, Monique van Velzen, Marieke Niesters, Albert Dahan, Celine M Laffont. Modeling buprenorphine reduction of fentanyl-induced respiratory depression. JCI insight. 2022 05; 7(9):. doi: 10.1172/jci.insight.156973. [PMID: 35316224]
  • Joanne Spetz, Laurie Hailer, Caryl Gay, Matthew Tierney, Laura Schmidt, Bethany Phoenix, Susan Chapman. Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements. JAMA network open. 2022 05; 5(5):e225996. doi: 10.1001/jamanetworkopen.2022.5996. [PMID: 35552728]
  • Sophie A Kitchen, Tonya J Campbell, Siyu Men, Nikki Bozinoff, Mina Tadrous, Tony Antoniou, Jennifer Wyman, Dan Werb, Charlotte Munro, Tara Gomes. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis. The International journal on drug policy. 2022 05; 103(?):103644. doi: 10.1016/j.drugpo.2022.103644. [PMID: 35272107]
  • John R Brooklyn, Marne Stothart, Mallory Stunell, Vanessa Melamede Berman, Danielle Rylant, Melanie Hanson. Characterizing the Clinical use of a Novel Video-assisted Dosing Protocol With Secure Medication Dispensers to Reduce Barriers to Opioid Treatment. Journal of addiction medicine. 2022 May; 16(3):310-316. doi: 10.1097/adm.0000000000000895. [PMID: 34282084]
  • Moosa Javdani, Abolfazl Barzegar, Pegah Khosravian, Mohammad Hashemnia. Evaluation of Inflammatory Response Due to Use of Controlled Release Drug Delivery System of Chitosan Hydrogel Loaded with Buprenorphine and Ketorolac in Rat with Experimental Proximal Tibial Epiphysis Defect. Journal of investigative surgery : the official journal of the Academy of Surgical Research. 2022 May; 35(5):996-1011. doi: 10.1080/08941939.2021.1989728. [PMID: 34666588]
  • Bradley D Stein, Brendan Saloner, Rose Kerber, Mark Sorbero, Adam J Gordon. Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020. Annals of emergency medicine. 2022 05; 79(5):441-450. doi: 10.1016/j.annemergmed.2022.01.042. [PMID: 35305851]
  • Raka Jain, Siddharth Sarkar, Nizamuddin Saifi, Shayani Ghosh. Urinalysis based assessment of compliance and drug use patterns in patients prescribed tramadol: A cross-sectional study from a tertiary care centre. Asian journal of psychiatry. 2022 May; 71(?):103080. doi: 10.1016/j.ajp.2022.103080. [PMID: 35305452]
  • Sarah M Allen, Taylor A Nichols, Janet Fawcett, Show Lin. Outcomes associated with once-daily versus multiple-daily dosing of buprenorphine/naloxone for opioid use disorder. The American journal on addictions. 2022 05; 31(3):173-179. doi: 10.1111/ajad.13267. [PMID: 35226393]
  • Treah Haggerty, Maryam Khodaverdi, Patricia Dekeseredy, Nathan Wood, Brian Hendricks, Jason Peklinsky, Cara L Sedney. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia. Journal of substance abuse treatment. 2022 05; 136(?):108687. doi: 10.1016/j.jsat.2021.108687. [PMID: 34903397]
  • Mahmoud Abdelwahab, Michelle Petrich, Heather Wang, Erin Walker, Erin M Cleary, Kara M Rood. Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder. American journal of obstetrics & gynecology MFM. 2022 05; 4(3):100582. doi: 10.1016/j.ajogmf.2022.100582. [PMID: 35123110]
  • Valerie S Ganetsky, Jessica Heil, Brianna Yates, Iris Jones, Krystal Hunter, Brandon Rivera, Lindsay Wilson, Matthew Salzman, Kaitlan E Baston. A Low-threshold Comprehensive Shared Medical Appointment Program for Perinatal Substance Use in an Underserved Population. Journal of addiction medicine. 2022 May; 16(3):e203-e209. doi: 10.1097/adm.0000000000000912. [PMID: 34510086]
  • Kim Corace, Kelly Suschinsky, Jennifer Wyman, Pamela Leece, Sue Cragg, Sarah Konefal, Priscille Pana, Susan Barrass, Amy Porath, Brian Hutton. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing. The International journal on drug policy. 2022 04; 102(?):103573. doi: 10.1016/j.drugpo.2021.103573. [PMID: 35123246]
  • Chinazo O Cunningham, Laila Khalid, Yuting Deng, Kristine Torres-Lockhart, Mariya Masyukova, Shenell Thomas, Chenshu Zhang, Tiffany Lu. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. Journal of substance abuse treatment. 2022 04; 135(?):108641. doi: 10.1016/j.jsat.2021.108641. [PMID: 34863608]
  • Elizabeth A Samuels, Utsha G Khatri, Hannah Snyder, Rachel S Wightman, Babak Tofighi, Noa Krawczyk. Buprenorphine Telehealth Treatment Initiation and Follow-Up During COVID-19. Journal of general internal medicine. 2022 Apr; 37(5):1331-1333. doi: 10.1007/s11606-021-07249-8. [PMID: 34981357]
  • Paul J Joudrey, Marynia Kolak, Qinyun Lin, Susan Paykin, Vidal Anguiano, Emily A Wang. Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder. JAMA network open. 2022 04; 5(4):e227028. doi: 10.1001/jamanetworkopen.2022.7028. [PMID: 35438757]
  • Cindy Xinxin Du, Julia Shi, Jeanette M Tetrault, Lynn M Madden, Declan T Barry. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Family practice. 2022 03; 39(2):234-240. doi: 10.1093/fampra/cmab166. [PMID: 34893825]
  • Nessreen Ghanem, Devin Dromgoole, Ahmad Hussein, Richard T Jermyn. Review of medication-assisted treatment for opioid use disorder. Journal of osteopathic medicine. 2022 Mar; 122(7):367-374. doi: 10.1515/jom-2021-0163. [PMID: 35285220]
  • Jacqueline Hodges, Marika Waselewski, William Harrington, Taylor Franklin, Kelly Schorling, Jacqueline Huynh, Alexa Tabackman, Kori Otero, Karen Ingersoll, Nassima Ait-Daoud Tiouririne, Tabor Flickinger, Rebecca Dillingham. Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown. Addiction science & clinical practice. 2022 03; 17(1):16. doi: 10.1186/s13722-022-00296-4. [PMID: 35255965]
  • Christopher J Hammond, Annabel Kady, Grace Park, Carol Vidal, Kevin Wenzel, Marc Fishman. Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment. Journal of addiction medicine. 2022 Mar; 16(2):e97-e104. doi: 10.1097/adm.0000000000000861. [PMID: 33973923]
  • Brendan Saloner, Noa Krawczyk, Keisha Solomon, Sean T Allen, Miles Morris, Katherine Haney, Susan G Sherman. Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey. The International journal on drug policy. 2022 03; 101(?):103537. doi: 10.1016/j.drugpo.2021.103537. [PMID: 34871945]
  • Tara Gomes, Tonya J Campbell, Sophie A Kitchen, Ria Garg, Nikki Bozinoff, Siyu Men, Mina Tadrous, Charlotte Munro, Tony Antoniou, Dan Werb, Jennifer Wyman. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. JAMA. 2022 03; 327(9):846-855. doi: 10.1001/jama.2022.1271. [PMID: 35230394]
  • Linda Peng, David Lawrence, Ximena A Levander. Challenges of Diagnosing and Managing Designer Benzodiazepine Dependence and Withdrawal: A Case Report. Journal of addiction medicine. 2022 Mar; 16(2):249-251. doi: 10.1097/adm.0000000000000869. [PMID: 34001772]
  • William N Dowd, Tami L Mark. Changes in Buprenorphine Prescribing to Medicaid Beneficiaries During the First Year of the COVID-19 Pandemic. JAMA network open. 2022 03; 5(3):e224058. doi: 10.1001/jamanetworkopen.2022.4058. [PMID: 35323952]
  • Marjorie A Bowman, Dean A Seehusen, Christy J W Ledford. This Issue's Emphasis: Inequity and COVID-19, Intertwined. Journal of the American Board of Family Medicine : JABFM. 2022 Mar; 35(2):215-218. doi: 10.3122/jabfm.2022.02.220037. [PMID: 35379708]
  • David Dadiomov, Rebecca Trotzky-Sirr, Andrew Shooshtari, Dima M Qato. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic. Drug and alcohol dependence. 2022 03; 232(?):109291. doi: 10.1016/j.drugalcdep.2022.109291. [PMID: 35033953]
  • Laura J Cremer, Amy Board, Gery P Guy, Lyna Schieber, Alice Asher, Erin M Parker. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020. Drug and alcohol dependence. 2022 03; 232(?):109192. doi: 10.1016/j.drugalcdep.2021.109192. [PMID: 35065513]
  • Andres Perez-Correa, Bilal Abbas, Lindsey Riback, Megan Ghiroli, Brianna Norton, Sean Murphy, Andrea Jakubowski, Benjamin T Hayes, Chinazo O Cunningham, Aaron D Fox. Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale. Contemporary clinical trials. 2022 03; 114(?):106674. doi: 10.1016/j.cct.2021.106674. [PMID: 34990854]
  • Sacha Uljon. An Adulterated Urine Buprenorphine Specimen. The primary care companion for CNS disorders. 2022 Feb; 24(2):. doi: 10.4088/pcc.21cr03007. [PMID: 35213940]
  • Larissa L Silva, Rebecca M Silvola, David M Haas, Sara K Quinney. Physiologically based pharmacokinetic modelling in pregnancy: Model reproducibility and external validation. British journal of clinical pharmacology. 2022 02; 88(4):1441-1451. doi: 10.1111/bcp.15018. [PMID: 34337764]
  • Daniel C Stokes, Jeanmarie Perrone. Increasing Short- and Long-Term Buprenorphine Treatment Capacity: Providing Waiver Training for Medical Students. Academic medicine : journal of the Association of American Medical Colleges. 2022 02; 97(2):182-187. doi: 10.1097/acm.0000000000003968. [PMID: 33538477]
  • Hamad Al Ghafri, Nael Hasan, Hesham Farouk Elarabi, Doa Radwan, Mansour Shawky, Samya Al Mamari, Tarek Abdelgawad, Abuelgasim El Rashid, Ayman Kodera, Helal Al Kathiri, Amanda J Lee, Shamil Wanigaratne. The impact of family engagement in opioid assisted treatment: Results from a randomised controlled trial. The International journal of social psychiatry. 2022 02; 68(1):166-170. doi: 10.1177/0020764020979026. [PMID: 33325311]
  • Ellen F Eaton, Ashutosh Tamhane, Wesli Turner, James L Raper, Michael S Saag, Karen L Cropsey. Safer in care: A pandemic-tested model of integrated HIV/OUD care. Drug and alcohol dependence. 2022 02; 231(?):109241. doi: 10.1016/j.drugalcdep.2021.109241. [PMID: 35007957]
  • Christopher J Hammond, Grace Park, Annabel Kady, Krutika Rathod, Naisa Rahman, Carol Vidal, Kevin Wenzel, Marc Fishman. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders. Journal of substance abuse treatment. 2022 02; 133(?):108495. doi: 10.1016/j.jsat.2021.108495. [PMID: 34218992]
  • Lewei A Lin, John C Fortney, Amy S B Bohnert, Lara N Coughlin, Lan Zhang, John D Piette. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder. Journal of substance abuse treatment. 2022 02; 133(?):108492. doi: 10.1016/j.jsat.2021.108492. [PMID: 34175175]
  • Richard H Cales, Shannon C Cales, Jacob Shreffler, Martin R Huecker. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth. Journal of substance abuse treatment. 2022 02; 133(?):108543. doi: 10.1016/j.jsat.2021.108543. [PMID: 34210567]
  • Ismene Petrakis, Sandra A Springer, Cynthia Davis, Elizabeth Ralevski, Lucy Gu, Robert Lew, John Hermos, Melynn Nuite, Adam J Gordon, Thomas R Kosten, Edward V Nunes, Robert Rosenheck, Andrew J Saxon, Robert Swift, Alexa Goldberg, Robert Ringer, Ryan Ferguson. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction science & clinical practice. 2022 01; 17(1):6. doi: 10.1186/s13722-022-00286-6. [PMID: 35101115]
  • Anna Cheng, Ryan Badolato, Andrew Segoshi, Ryan McDonald, Mia Malone, Kumar Vasudevan, Beita Badiei, Allison Sugarman, Ross Macdonald, Jasdeep Mangat, Jonathan Giftos, Joshua D Lee, Babak Tofighi. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addiction science & clinical practice. 2022 01; 17(1):4. doi: 10.1186/s13722-022-00288-4. [PMID: 35093164]
  • Benjamin A Barsky, Alisa B Busch, Sadiq Y Patel, Ateev Mehrotra, Haiden A Huskamp. Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage. JAMA network open. 2022 01; 5(1):e2142531. doi: 10.1001/jamanetworkopen.2021.42531. [PMID: 34989798]
  • Siri Shastry, Ishak Nobel, Lisa R Allen, Lynne D Richardson, Kavey Vidal, Alex F Manini. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity. The American journal of emergency medicine. 2022 Jan; 51(?):114-118. doi: 10.1016/j.ajem.2021.10.012. [PMID: 34735968]
  • Claudia C Tussey, Margaret D Reyes, Rosalinda B Thomas, Charlotte T Boyd, John G Spangler, Julienne K Kirk. Utility of the group medical visit model for medication-assisted therapy. Journal of opioid management. 2022 Jan; 18(1):69-74. doi: 10.5055/jom.2022.0696. [PMID: 35238015]
  • Lynsey Avalone, Carla King, Dennis Popeo, Charles Perkel, Chidinma J Abara, Rebecca Linn-Walton, Vladimir Gasca, Laurie Vitagliano, Charles Barron, Omar Fattal. Increased Attendance During Rapid Implementation of Telehealth for Substance Use Disorders During COVID-19 at the Largest Public Hospital System in the United States. Substance use & misuse. 2022; 57(8):1322-1327. doi: 10.1080/10826084.2022.2079140. [PMID: 35611875]
  • Babak Tofighi, Jennifer McNeely, Jenny Yang, Anil Thomas, Daniel Schatz, Timothy Reed, Noa Krawczyk. Outcomes of a NYC Public Hospital System Low-Threshold Tele-Buprenorphine Bridge Clinic at 1 Year. Substance use & misuse. 2022; 57(8):1337-1340. doi: 10.1080/10826084.2022.2069269. [PMID: 35481461]
  • Robert Harris, Amanda Rosecrans, Meredith Zoltick, Catherine Willman, Ronald Saxton, Margaret Cotterell, Joy Bell, Ingrid Blackwell, Kathleen R Page. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program. Drug and alcohol dependence. 2022 01; 230(?):109187. doi: 10.1016/j.drugalcdep.2021.109187. [PMID: 34890927]
  • Charles D Brackett, Matthew Duncan, Joanne Fadale Wagner, Laura Fineberg, Sally Kraft. Multidisciplinary treatment of opioid use disorder in primary care using the collaborative care model. Substance abuse. 2022; 43(1):240-244. doi: 10.1080/08897077.2021.1932698. [PMID: 34086531]
  • Elizabeth A McCarthy, Daniel Dischino, Caroline Maguire, Silvia Leon, Rajae Talbi, Eugene Cheung, Claudio D Schteingart, Pierre J M Rivière, Susan D Reed, Robert A Steiner, Victor M Navarro. Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms. The Journal of clinical endocrinology and metabolism. 2022 01; 107(1):e328-e347. doi: 10.1210/clinem/dgab602. [PMID: 34387319]
  • Ashley C Lensch, Essence Hairston, Ginny Carter, Hendrée E Jones. Pregnant Patients Using Opioids: Treatment Access Barriers in the Age of COVID-19. Journal of addiction medicine. 2022 Jan; 16(1):e44-e47. doi: 10.1097/adm.0000000000000826. [PMID: 33606424]
  • Suzan M Walters, David C Perlman, Honoria Guarino, Pedro Mateu-Gelabert, David Frank. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities. Substance use & misuse. 2022; 57(7):1144-1153. doi: 10.1080/10826084.2022.2064509. [PMID: 35443862]
  • Babak Tofighi, Jennifer McNeely, Dalia Walzer, Kush Fansiwala, Adam Demner, Chloe S Chaudhury, Ipsita Subudhi, Daniel Schatz, Timothy Reed, Noa Krawczyk. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic. Journal of addiction medicine. 2022 Jan; 16(1):e40-e43. doi: 10.1097/adm.0000000000000809. [PMID: 33560696]
  • Ximena A Levander, Haven Wheelock, Justine Pope, Abby Lee, Kerith Hartmann, Sarah Abuelkhair, Jessica L Gregg, Bradley M Buchheit. Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19. Journal of addiction medicine. 2022 Jan; 16(1):e56-e58. doi: 10.1097/adm.0000000000000811. [PMID: 34374502]
  • Kristi Hill, Laura Nussdorf, Julia D Mount, Rachel Silk, Chloe Gross, David Sternberg, Phyllis Bijole, Miriam Jones, Randy Kier, Dana Mccullough, Poonam Mathur, Shyam Kottilil, Henry Masur, Sarah Kattakuzhy, Elana S Rosenthal. Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment. Journal of addiction medicine. 2022 Jan; 16(1):10-17. doi: 10.1097/adm.0000000000000807. [PMID: 33560694]
  • Laurence M Moss, Marijke Hyke Algera, Robert Dobbins, Frank Gray, Stephanie Strafford, Amy Heath, Monique van Velzen, Jules A A C Heuberger, Marieke Niesters, Erik Olofsen, Celine M Laffont, Albert Dahan, Geert Jan Groeneveld. Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. PloS one. 2022; 17(1):e0256752. doi: 10.1371/journal.pone.0256752. [PMID: 35085249]
  • Traci C Green, Jeffrey Bratberg, Adriane N Irwin, Jesse Boggis, Mary Gray, Gillian Leichtling, Derek Bolivar, Anthony Floyd, Zain Al-Jammali, Jenny Arnold, Ryan Hansen, Daniel Hartung. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies. Substance abuse. 2022; 43(1):901-905. doi: 10.1080/08897077.2021.2010162. [PMID: 35213293]
  • Brian Chan, Christina Bougatsos, Kelsey C Priest, Dennis McCarty, Sara Grusing, Roger Chou. Opioid treatment programs, telemedicine and COVID-19: A scoping review. Substance abuse. 2022; 43(1):539-546. doi: 10.1080/08897077.2021.1967836. [PMID: 34520702]
  • Lila Flavin, Babak Tofighi, Noa Krawczyk, Daniel Schatz, Jennifer McNeely, Jenna Butner. Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report. Journal of addiction medicine. 2022 Jan; 16(1):e59-e61. doi: 10.1097/adm.0000000000000836. [PMID: 35120069]
  • Christine Ramdin, Marshall Guo, Scott Fabricant, Cynthia Santos, Lewis Nelson. The Impact of a Peer-Navigator Program on Naloxone Distribution and Buprenorphine Utilization in the Emergency Department. Substance use & misuse. 2022; 57(4):581-587. doi: 10.1080/10826084.2021.2023187. [PMID: 34970942]
  • Kelsey C Priest, Caroline A King, Honora Englander, Travis I Lovejoy, Dennis McCarty. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis. Substance abuse. 2022; 43(1):1251-1259. doi: 10.1080/08897077.2022.2074601. [PMID: 35670778]
  • Peter C Treitler, Cadence F Bowden, James Lloyd, Michael Enich, Amesika N Nyaku, Stephen Crystal. Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms. Journal of substance abuse treatment. 2022 01; 132(?):108514. doi: 10.1016/j.jsat.2021.108514. [PMID: 34098210]
  • Eden D Alamaw, Benjamin D Franco, Katechan Jampachaisri, Monika K Huss, Cholawat Pacharinsak. Extended-release Buprenorphine, an FDAindexed Analgesic, Attenuates Mechanical Hypersensitivity in Rats (Rattus norvegicus). Journal of the American Association for Laboratory Animal Science : JAALAS. 2022 01; 61(1):81-88. doi: 10.30802/aalas-jaalas-21-000081. [PMID: 34903316]
  • William J Parish, Tami L Mark, Gary A Zarkin, Ellen Weber. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States. Addiction (Abingdon, England). 2022 01; 117(1):141-150. doi: 10.1111/add.15585. [PMID: 34033177]
  • Jessica L Coker, Shona L Ray-Griffith, Cody McLeod, Xiaotong Han, Michael Mancino, Gregory L Kearns, Zachary N Stowe. Clearance of buprenorphine during pregnancy and neonatal outcomes. Archives of women's mental health. 2021 12; 24(6):933-939. doi: 10.1007/s00737-021-01128-1. [PMID: 33864131]
  • Rohan Chalasani, Jared M Shinabery, Carrie Thomas Goetz, Chung-Chou H Chang, Qingnan Yang, Katie J Suda, Walid F Gellad. Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020. Journal of general internal medicine. 2021 12; 36(12):3915-3917. doi: 10.1007/s11606-021-07083-y. [PMID: 34378112]
  • Bradley M Buchheit, Haven Wheelock, Abby Lee, Kimberly Brandt, Jessica Gregg. Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects. Journal of substance abuse treatment. 2021 12; 131(?):108444. doi: 10.1016/j.jsat.2021.108444. [PMID: 34098299]
  • Caroul Chawar, Alannah Hillmer, Stephanie Sanger, Alessia D'Elia, Balpreet Panesar, Lucy Guan, Dave Xiaofei Xie, Nandini Bansal, Aamna Abdullah, Flavio Kapczinski, Guillaume Pare, Lehana Thabane, Zainab Samaan. A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder. Addiction science & clinical practice. 2021 11; 16(1):70. doi: 10.1186/s13722-021-00278-y. [PMID: 34838141]
  • Shoshana V Aronowitz, Eden Engel-Rebitzer, Abby Dolan, Kehinde Oyekanmi, David Mandell, Zachary Meisel, Eugenia South, Margaret Lowenstein. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives. Harm reduction journal. 2021 11; 18(1):119. doi: 10.1186/s12954-021-00572-7. [PMID: 34823538]
  • Sabine Plattner, Marion Pavlic, Florian Pitterl, Birthe Schubert. Consumption of the Sugar Substitute Stevia Leads to Cross-Reactivity of CEDIA® Buprenorphine II Immunoassay. Journal of analytical toxicology. 2021 Nov; 45(9):1052-1057. doi: 10.1093/jat/bkaa167. [PMID: 33104778]
  • Miriam Komaromy, Mary Tomanovich, Jessica L Taylor, Glorimar Ruiz-Mercado, Simeon D Kimmel, Sarah M Bagley, Kelley M Saia, Eileen Costello, Tae Woo Park, Colleen LaBelle, Zoe Weinstein, Alexander Y Walley. Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. Journal of addiction medicine. 2021 Nov; 15(6):448-451. doi: 10.1097/adm.0000000000000791. [PMID: 33298750]
  • Ryan R Cook, Randy Torralva, Caroline King, Paula J Lum, Hansel Tookes, Canyon Foot, Pamela Vergara-Rodriguez, Allan Rodriguez, Laura Fanucchi, Gregory M Lucas, Elizabeth N Waddell, P Todd Korthuis. Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. Drug and alcohol dependence. 2021 11; 228(?):109077. doi: 10.1016/j.drugalcdep.2021.109077. [PMID: 34600253]
  • Elizabeth R Houston, Sarah M Tan, Samantha M Thomas, Ulana L Stasula, Mollie K Burton, Heather K Knych, Lon V Kendall. Pharmacokinetics and Efficacy of a Long-lasting, Highly Concentrated Buprenorphine Solution in Rats. Journal of the American Association for Laboratory Animal Science : JAALAS. 2021 11; 60(6):667-674. doi: 10.30802/aalas-jaalas-21-000055. [PMID: 34736551]
  • Samantha Young, Kanna Hayashi, Cameron Grant, M J Milloy, Kora DeBeck, Evan Wood, Nadia Fairbairn. Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada. Drug and alcohol dependence. 2021 11; 228(?):109006. doi: 10.1016/j.drugalcdep.2021.109006. [PMID: 34509737]
  • David T Moore, Dora Lendvai Wischik, Christina M Lazar, Gabriela Garcia Vassallo, Marc I Rosen. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub. Preventive medicine. 2021 11; 152(Pt 2):106603. doi: 10.1016/j.ypmed.2021.106603. [PMID: 33974959]
  • Page H Myers, David R Goulding, Rebecca A Wiltshire, Christopher A McGee, Angela B Dickerson, Molly M Comins, Min Shi, Grace E Kissling, Fred B Lih, Leesa J Deterding, Kathy E Laber-Laird, Terry L Blankenship-Paris. Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine. Journal of the American Association for Laboratory Animal Science : JAALAS. 2021 11; 60(6):661-666. doi: 10.30802/aalas-jaalas-21-000028. [PMID: 34740385]